ZA200208940B - 1,4-diazepan-2,5-dione derivatives and their use as NK-1 receptor antagonists. - Google Patents
1,4-diazepan-2,5-dione derivatives and their use as NK-1 receptor antagonists. Download PDFInfo
- Publication number
- ZA200208940B ZA200208940B ZA200208940A ZA200208940A ZA200208940B ZA 200208940 B ZA200208940 B ZA 200208940B ZA 200208940 A ZA200208940 A ZA 200208940A ZA 200208940 A ZA200208940 A ZA 200208940A ZA 200208940 B ZA200208940 B ZA 200208940B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- formula
- benzyl
- dichloro
- methyl
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title claims description 8
- 229940044551 receptor antagonist Drugs 0.000 title claims description 8
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title claims description 7
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title claims description 7
- XMOKZLVOWBOPCO-UHFFFAOYSA-N 1,4-diazepane-2,5-dione Chemical class O=C1CCNC(=O)CN1 XMOKZLVOWBOPCO-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 105
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- KEZRMJKVMBGSSQ-QHCPKHFHSA-N (3s)-3-(1h-indol-3-ylmethyl)-1-[(2-methoxynaphthalen-1-yl)methyl]-1,4-diazepane-2,5-dione Chemical compound COC1=CC=C2C=CC=CC2=C1CN(C1=O)CCC(=O)N[C@H]1CC1=CNC2=CC=CC=C12 KEZRMJKVMBGSSQ-QHCPKHFHSA-N 0.000 claims description 2
- UIJZJBWXEAHGRX-QFIPXVFZSA-N (5s)-5-[(3,4-dichlorophenyl)methyl]-7-[(2-methoxynaphthalen-1-yl)methyl]-8,9-dihydro-5h-[1,2,4]triazolo[4,3-d][1,4]diazepin-6-one Chemical compound C([C@@H]1N2C=NN=C2CCN(C1=O)CC1=C2C=CC=CC2=CC=C1OC)C1=CC=C(Cl)C(Cl)=C1 UIJZJBWXEAHGRX-QFIPXVFZSA-N 0.000 claims description 2
- WRRPNMIWURZYJL-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-1-[(2-ethoxynaphthalen-1-yl)methyl]-1,4-diazepane-2,5-dione Chemical compound CCOC1=CC=C2C=CC=CC2=C1CN(C1=O)CCC(=O)NC1CC1=CC=C(Cl)C(Cl)=C1 WRRPNMIWURZYJL-UHFFFAOYSA-N 0.000 claims description 2
- UGZUGRXVXCRQIR-UHFFFAOYSA-N 5-[(3,4-dichlorophenyl)methyl]-3-methyl-7-naphthalen-1-yl-8,9-dihydro-5h-[1,2,4]triazolo[4,3-d][1,4]diazepin-6-one Chemical compound N12C(C)=NN=C2CCN(C=2C3=CC=CC=C3C=CC=2)C(=O)C1CC1=CC=C(Cl)C(Cl)=C1 UGZUGRXVXCRQIR-UHFFFAOYSA-N 0.000 claims description 2
- BMWMFZCWYHPVRA-UHFFFAOYSA-N 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-[(3,4-dichlorophenyl)methyl]-3-(2-morpholin-4-ylethyl)-8,9-dihydro-5h-[1,2,4]triazolo[4,3-d][1,4]diazepin-6-one Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(C(CC=3C=C(Cl)C(Cl)=CC=3)N3C(CCN4CCOCC4)=NN=C3CC2)=O)=C1 BMWMFZCWYHPVRA-UHFFFAOYSA-N 0.000 claims description 2
- SUAYOYQCDBVEFF-UHFFFAOYSA-N 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-[(3,4-dichlorophenyl)methyl]-3-[(dimethylamino)methyl]-8,9-dihydro-5h-[1,2,4]triazolo[4,3-d][1,4]diazepin-6-one Chemical compound O=C1C(CC=2C=C(Cl)C(Cl)=CC=2)N2C(CN(C)C)=NN=C2CCN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 SUAYOYQCDBVEFF-UHFFFAOYSA-N 0.000 claims description 2
- CCJZBQWKUNVPMG-UHFFFAOYSA-N 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-[(3,4-dichlorophenyl)methyl]-8,9-dihydro-5h-[1,2,4]triazolo[4,3-d][1,4]diazepin-6-one Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(C(CC=3C=C(Cl)C(Cl)=CC=3)N3C=NN=C3CC2)=O)=C1 CCJZBQWKUNVPMG-UHFFFAOYSA-N 0.000 claims description 2
- RZYUXTUJQOLCHE-UHFFFAOYSA-N FC(C=1C=C(CN2C(C(N3C(=NN=C3CC2C)N2CCCCC2)CC2=CC(=C(C=C2)Cl)Cl)=O)C=C(C1)C(F)(F)F)(F)F Chemical compound FC(C=1C=C(CN2C(C(N3C(=NN=C3CC2C)N2CCCCC2)CC2=CC(=C(C=C2)Cl)Cl)=O)C=C(C1)C(F)(F)F)(F)F RZYUXTUJQOLCHE-UHFFFAOYSA-N 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 4
- FCSJYMFPCWZEOQ-FQEVSTJZSA-N (3s)-1-[[2,8-bis(trifluoromethyl)quinolin-4-yl]methyl]-3-(1h-indol-3-ylmethyl)-1,4-diazepane-2,5-dione Chemical compound C=12C=CC=C(C(F)(F)F)C2=NC(C(F)(F)F)=CC=1CN(C1=O)CCC(=O)N[C@H]1CC1=CNC2=CC=CC=C12 FCSJYMFPCWZEOQ-FQEVSTJZSA-N 0.000 claims 1
- NQUZJPALTDPICI-QFIPXVFZSA-N (3s)-3-[(3,4-dichlorophenyl)methyl]-1-[(2-methylnaphthalen-1-yl)methyl]-1,4-diazepane-2,5-dione Chemical compound C([C@@H]1NC(=O)CCN(C1=O)CC1=C2C=CC=CC2=CC=C1C)C1=CC=C(Cl)C(Cl)=C1 NQUZJPALTDPICI-QFIPXVFZSA-N 0.000 claims 1
- WIFFSTLFQDZHEH-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-1-[(2-methoxynaphthalen-1-yl)methyl]-3-methyl-4-pyridin-3-yl-1,4-diazepane-2,5-dione Chemical compound COC1=CC=C2C=CC=CC2=C1CN(C(C1(CC=2C=C(Cl)C(Cl)=CC=2)C)=O)CCC(=O)N1C1=CC=CN=C1 WIFFSTLFQDZHEH-UHFFFAOYSA-N 0.000 claims 1
- STOOOQRWUYHMTF-UHFFFAOYSA-N 4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[(3,4-dichlorophenyl)methyl]-7-(propylamino)-5,6-dihydro-2h-1,4-diazepin-3-one Chemical compound O=C1N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCC(NCCC)=NC1CC1=CC=C(Cl)C(Cl)=C1 STOOOQRWUYHMTF-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 18
- 102100024304 Protachykinin-1 Human genes 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- -1 for example Chemical group 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 101800003906 Substance P Proteins 0.000 description 9
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 8
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 7
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 5
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000003141 Tachykinin Human genes 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- WYLQARGYFXBZMD-UHFFFAOYSA-N n-[chloro(dimethylamino)phosphoryl]-n-methylmethanamine Chemical compound CN(C)P(Cl)(=O)N(C)C WYLQARGYFXBZMD-UHFFFAOYSA-N 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 108060008037 tachykinin Proteins 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- ZDEQBVQEYCMRPC-NRFANRHFSA-N (3s)-3-[(3,4-dichlorophenyl)methyl]-1-[(2-methoxynaphthalen-1-yl)methyl]-1,4-diazepane-2,5-dione Chemical compound C([C@@H]1NC(=O)CCN(C1=O)CC1=C2C=CC=CC2=CC=C1OC)C1=CC=C(Cl)C(Cl)=C1 ZDEQBVQEYCMRPC-NRFANRHFSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000007124 Tachykinin Receptors Human genes 0.000 description 2
- 108010072901 Tachykinin Receptors Proteins 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000002462 tachykinin receptor antagonist Substances 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QRCZETAZRAHTIL-KRWDZBQOSA-N (3s)-1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3,4-dichlorophenyl)methyl]-1,4-diazepane-2,5-dione Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C([C@H](CC=3C=C(Cl)C(Cl)=CC=3)NC(=O)CC2)=O)=C1 QRCZETAZRAHTIL-KRWDZBQOSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- QRCZETAZRAHTIL-UHFFFAOYSA-N 1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3,4-dichlorophenyl)methyl]-1,4-diazepane-2,5-dione Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(C(CC=3C=C(Cl)C(Cl)=CC=3)NC(=O)CC2)=O)=C1 QRCZETAZRAHTIL-UHFFFAOYSA-N 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- AULJDODYNDIOLA-UHFFFAOYSA-N 2,8-bis(trifluoromethyl)quinoline-4-carbaldehyde Chemical compound C1=CC=C(C(F)(F)F)C2=NC(C(F)(F)F)=CC(C=O)=C21 AULJDODYNDIOLA-UHFFFAOYSA-N 0.000 description 1
- YIQGLTKAOHRZOL-UHFFFAOYSA-N 2-methoxynaphthalene-1-carbaldehyde Chemical compound C1=CC=CC2=C(C=O)C(OC)=CC=C21 YIQGLTKAOHRZOL-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- INHHESUOUFCARG-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-1-(naphthalen-1-ylmethyl)-1,4-diazepane-2,5-dione Chemical compound C1=C(Cl)C(Cl)=CC=C1CC1C(=O)N(CC=2C3=CC=CC=C3C=CC=2)CCC(=O)N1 INHHESUOUFCARG-UHFFFAOYSA-N 0.000 description 1
- NHFNQNROTZRAEM-UHFFFAOYSA-N 3-[[3,5-bis(trifluoromethyl)phenyl]methylamino]propanoic acid Chemical compound OC(=O)CCNCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NHFNQNROTZRAEM-UHFFFAOYSA-N 0.000 description 1
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- RRRCPCOJPQLWEP-UHFFFAOYSA-N 3-hydroxytriazolo[4,5-b]pyridine Chemical compound C1=CN=C2N(O)N=NC2=C1.C1=CN=C2N(O)N=NC2=C1 RRRCPCOJPQLWEP-UHFFFAOYSA-N 0.000 description 1
- ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- FUPJDCKHWRGZIH-UHFFFAOYSA-N 4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[(3,4-dichlorophenyl)methyl]-7-(propylamino)-5,6-dihydro-2h-1,4-diazepin-3-one;hydrochloride Chemical compound Cl.O=C1C(CC=2C=C(Cl)C(Cl)=CC=2)NC(=NCCC)CCN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 FUPJDCKHWRGZIH-UHFFFAOYSA-N 0.000 description 1
- MVXMNHYVCLMLDD-UHFFFAOYSA-N 4-methoxynaphthalene-1-carbaldehyde Chemical compound C1=CC=C2C(OC)=CC=C(C=O)C2=C1 MVXMNHYVCLMLDD-UHFFFAOYSA-N 0.000 description 1
- JHWLRBLLRLHDDP-UHFFFAOYSA-N 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-[(3,4-dichlorophenyl)methyl]-3-(1-methylpiperidin-2-yl)-8,9-dihydro-5h-[1,2,4]triazolo[4,3-d][1,4]diazepin-6-one Chemical compound CN1CCCCC1C1=NN=C2N1C(CC=1C=C(Cl)C(Cl)=CC=1)C(=O)N(CC=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)CC2 JHWLRBLLRLHDDP-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 101100167365 Caenorhabditis elegans cha-1 gene Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 102000028517 Neuropeptide receptor Human genes 0.000 description 1
- 108070000018 Neuropeptide receptor Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000021957 Ocular injury Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000012545 Psychophysiologic disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- PSACHCMMPFMFAJ-UHFFFAOYSA-N nmm n-methylmorpholine Chemical compound CN1CCOCC1.CN1CCOCC1 PSACHCMMPFMFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ZPHBZEQOLSRPAK-XLCYBJAPSA-N phosphoramidon Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)P(O)(=O)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O ZPHBZEQOLSRPAK-XLCYBJAPSA-N 0.000 description 1
- 108010072906 phosphoramidon Proteins 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000002466 tachykinin receptor agonist Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00111249 | 2000-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200208940B true ZA200208940B (en) | 2004-02-04 |
Family
ID=8168838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200208940A ZA200208940B (en) | 2000-05-25 | 2002-11-04 | 1,4-diazepan-2,5-dione derivatives and their use as NK-1 receptor antagonists. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6452001B2 (enExample) |
| EP (1) | EP1296961B1 (enExample) |
| JP (1) | JP4060596B2 (enExample) |
| KR (1) | KR100526696B1 (enExample) |
| CN (1) | CN1178923C (enExample) |
| AR (1) | AR028607A1 (enExample) |
| AT (1) | ATE353881T1 (enExample) |
| AU (2) | AU2001281778B2 (enExample) |
| BR (1) | BR0111062A (enExample) |
| CA (1) | CA2409842C (enExample) |
| DE (1) | DE60126614T2 (enExample) |
| DK (1) | DK1296961T3 (enExample) |
| ES (1) | ES2280392T3 (enExample) |
| MX (1) | MXPA02011464A (enExample) |
| PE (1) | PE20011266A1 (enExample) |
| PT (1) | PT1296961E (enExample) |
| WO (1) | WO2001090083A1 (enExample) |
| ZA (1) | ZA200208940B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2598762A1 (en) | 2005-02-25 | 2006-08-31 | F. Hoffmann-La Roche Ag | Tablets with improved drug substance dispersibility |
| DE602006016168D1 (de) * | 2005-12-29 | 2010-09-23 | Immupharma France Sa | 1,3,5-triazepin-dionen zur Behandlung von Malaria |
| US7777030B2 (en) | 2005-12-29 | 2010-08-17 | Centre National de la Recherge Scientifique (CNRS) | Compositions and methods for the treatment and prevention of disease |
| AU2006331357B2 (en) * | 2005-12-29 | 2012-05-17 | Immupharma France Sa | Compositions and methods for synthesizing novel heterocyclic therapeutics |
| JP2009522236A (ja) * | 2005-12-29 | 2009-06-11 | イミュファルマ・フランス・エスアー | マラリアまたはエイズの処置のためのアザ複素環化合物 |
| AU2006331355B2 (en) * | 2005-12-29 | 2011-09-29 | Immupharma France Sa | Compositions and methods for the inhibition of phospholipase A2 |
| WO2007139992A2 (en) * | 2006-05-26 | 2007-12-06 | Novartis Ag | ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS |
| US8093268B2 (en) | 2007-01-24 | 2012-01-10 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) |
| KR101044833B1 (ko) * | 2010-02-10 | 2011-06-28 | (주)혜성나노텍 | 무차광 온실 보온커텐 종형 개폐장치 |
| CN103951624B (zh) * | 2010-08-26 | 2019-04-16 | 兴和株式会社 | 1,4-二氮杂环庚烷衍生物或其盐的制造方法 |
| CA2839385C (en) | 2011-06-24 | 2018-10-30 | Construction Research & Technology Gmbh | Cementitious composition and admixture |
| CN108358893A (zh) * | 2018-02-10 | 2018-08-03 | 安徽唯诗杨信息科技有限公司 | 一种一锅法合成四氢化苯并-[1,4]-二氮杂环庚烷衍生物的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4022765A (en) | 1975-01-06 | 1977-05-10 | E. R. Squibb & Sons, Inc. | Triazolo[4,3-d][1,4]benzodiazepine-6-ones |
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| IL112134A (en) | 1993-12-29 | 1999-12-22 | Merck Sharp & Dohme | Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| US5719156A (en) | 1995-05-02 | 1998-02-17 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
-
2001
- 2001-05-14 US US09/854,885 patent/US6452001B2/en not_active Expired - Fee Related
- 2001-05-18 DK DK01960225T patent/DK1296961T3/da active
- 2001-05-18 AU AU2001281778A patent/AU2001281778B2/en not_active Ceased
- 2001-05-18 ES ES01960225T patent/ES2280392T3/es not_active Expired - Lifetime
- 2001-05-18 KR KR10-2002-7015837A patent/KR100526696B1/ko not_active Expired - Fee Related
- 2001-05-18 DE DE60126614T patent/DE60126614T2/de not_active Expired - Lifetime
- 2001-05-18 EP EP01960225A patent/EP1296961B1/en not_active Expired - Lifetime
- 2001-05-18 WO PCT/EP2001/005723 patent/WO2001090083A1/en not_active Ceased
- 2001-05-18 CN CNB018099335A patent/CN1178923C/zh not_active Expired - Fee Related
- 2001-05-18 AU AU8177801A patent/AU8177801A/xx active Pending
- 2001-05-18 BR BR0111062-4A patent/BR0111062A/pt not_active Application Discontinuation
- 2001-05-18 AT AT01960225T patent/ATE353881T1/de not_active IP Right Cessation
- 2001-05-18 MX MXPA02011464A patent/MXPA02011464A/es active IP Right Grant
- 2001-05-18 CA CA002409842A patent/CA2409842C/en not_active Expired - Fee Related
- 2001-05-18 JP JP2001586272A patent/JP4060596B2/ja not_active Expired - Fee Related
- 2001-05-18 PT PT01960225T patent/PT1296961E/pt unknown
- 2001-05-21 PE PE2001000458A patent/PE20011266A1/es not_active Application Discontinuation
- 2001-05-23 AR ARP010102436A patent/AR028607A1/es unknown
-
2002
- 2002-11-04 ZA ZA200208940A patent/ZA200208940B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60126614D1 (de) | 2007-03-29 |
| AR028607A1 (es) | 2003-05-14 |
| BR0111062A (pt) | 2003-06-10 |
| KR20030003759A (ko) | 2003-01-10 |
| JP2003534332A (ja) | 2003-11-18 |
| DE60126614T2 (de) | 2007-11-22 |
| CA2409842A1 (en) | 2001-11-29 |
| DK1296961T3 (da) | 2007-06-04 |
| ES2280392T3 (es) | 2007-09-16 |
| EP1296961A1 (en) | 2003-04-02 |
| JP4060596B2 (ja) | 2008-03-12 |
| MXPA02011464A (es) | 2003-04-25 |
| US6452001B2 (en) | 2002-09-17 |
| ATE353881T1 (de) | 2007-03-15 |
| KR100526696B1 (ko) | 2005-11-08 |
| AU8177801A (en) | 2001-12-03 |
| PT1296961E (pt) | 2007-05-31 |
| CN1430611A (zh) | 2003-07-16 |
| EP1296961B1 (en) | 2007-02-14 |
| CA2409842C (en) | 2008-07-29 |
| WO2001090083A1 (en) | 2001-11-29 |
| CN1178923C (zh) | 2004-12-08 |
| US20020010174A1 (en) | 2002-01-24 |
| PE20011266A1 (es) | 2001-12-14 |
| AU2001281778B2 (en) | 2005-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5652246A (en) | Piperidine compounds | |
| US5723464A (en) | Piperazine derivatives | |
| FI114795B (fi) | Aroyylipiperidiinijohdannaiset | |
| US5322849A (en) | Benzoxazalinonyl and benzothiazolinonyl ethyl isonicotine amides and piperidonamides | |
| NZ225706A (en) | 2-((4-piperidyl)methyl)-1,2,3,4-tetrahydro-9h-pyrido(3,4-b) indole derivatives and their preparation | |
| JP2008508337A (ja) | インドリジンカルボキサミド並びにそのアザ及びジアザ誘導体 | |
| JPH10506399A (ja) | １−アシル−４−マリファチルアミノピペリジン化合物 | |
| TW201326143A (zh) | Ｇ蛋白偶合ｍａｓ受體之調節劑及與其相關病症之治療 | |
| NZ230068A (en) | Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions | |
| JP2011509961A (ja) | 置換スルホンアミド誘導体 | |
| JP2011509962A (ja) | 置換スルホンアミド誘導体 | |
| JP5487100B2 (ja) | アデノシンａ３受容体リガンドとしてのトリアゾロ［１，５−ａ］キノリン | |
| WO2022136914A1 (en) | Tyk2 inhibitors and uses thereof | |
| US5714487A (en) | 2,7-substituted octahydro-pyrrolo 1,2-a!pyrazine derivatives | |
| CA2409842C (en) | 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists | |
| AU2001281778A1 (en) | 1,4-diazepan-2,5-dione derivatives and their use as NK-1 receptor antagonists | |
| SK284802B6 (sk) | Deriváty N-triazolylmetylpiperazínu s antagonistickou aktivitou k neurokinínovým receptorom, spôsob ich výroby, medziprodukt a liečivá s ich obsahom | |
| CN112041319A (zh) | 三唑、咪唑和吡咯稠合的哌嗪衍生物及其作为mGlu5受体的调节剂的应用 | |
| JP2004505110A (ja) | ３位置換イソキノリン−１−イル誘導体 | |
| JP2008503560A (ja) | ジアザビシクロ系のヒスタミン−３受容体アンタゴニスト | |
| US5081128A (en) | 2,3-dihydro-1h-isoindole derivatives and their application in therapy | |
| US5332738A (en) | Imidazolidine antipsychotic agents | |
| IL98372A (en) | ((1-arylpyrrolidin-2-yl)methyl) piperazine derivatives their preparation and their application in therapeutics | |
| MXPA99001751A (en) | Piperazino derivatives as neurokinin antagonists | |
| KR20050023401A (ko) | 무스카린 수용체 길항제로서 사용가능한 3,6-이치환된아자비시클로 [3.1.0]헥산 유도체 |